Synthesis and assessment of analgesic activity of a new 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidin-4-olate sodium


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-sodium olate synthesis (test compound, target compound) and its acute toxicity, analgesic activity in silico and in vivo evaluation. Material and methods. The target compound was obtained by the interaction of 5-butyl-6-hydroxy-2,3-diphenylpyrimidin-4 (3H) -OH radicals and an sodium hydroxide aqueous solution equimolar amount. The structure was proved by NMR 1H and 13C spectroscopy. The test compound acute toxicity prediction was carried out using the GUSAR software. Acute toxicity in vivo was determined in white outbred male mice. Biological activity computer screening was performed using the PASS program located on a web service freely accessible via the Internet. For the analgesic activity experimental assessment, two models were used: tail-flicking ofthe tail from heat radiation and acetic acid cramps. Results. Sodium 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-olate was synthesized in quantitative yield. The structure is proved using 1H and 13C NMR spectroscopy. The acute toxicity predicted and experimental data allow to classify the compound under study as moderately hazardous. During the biological activity screening with the PASS program help, data on the alleged analgesic effect we re obtained. The analgesic activity study in vivo showed that the target compound hasa pronounced effect. Conclusion. A new compound, 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-sodium olate, was synthesized. Its structure has been proven using modern physicochemical analysis methods. The computer modelling results made it possible to determine the toxicity class and potential biological activity. With the experimental pharmacological studies help, it was proved that the studied compound has a toxicity low level and shows pronounced analgesic activity.

Full Text

Restricted Access

About the authors

E. V Kuvaeva

Saint-Petersburg State Chemical and Pharmaceutical University

Email: elena.kuvaeva@pharminnotech.com
Ph.D.(Pharm.), Associate Professor, Department of Organic Chemistry

D. A Kolesnik

Saint-Petersburg State Chemical and Pharmaceutical University

Email: denis.kolesnik@spcpu.ru
Post-graduate Student

P. O Levshukova

Saint-Petersburg State Chemical and Pharmaceutical University

Email: levshukova.polina@pharminnotech.com
Student

D. Y Ivkin

Saint-Petersburg State Chemical and Pharmaceutical University

Email: dmitry.ivkin@pharminnotech.com
Ph.D.(Biol,), Associate Professor, Department of Pharmacology and Clinical Pharmacology

I. P Yakovlev

Saint-Petersburg State Chemical and Pharmaceutical University

Email: igor.yakovlev@pharminnotech.com
Dr.Sc. (Chem.), Professor, Head of the Department of Organic Chemistry

References

  1. Государственный реестр лекарственных средств [справочная система]. URL: grls.rosminzdrav.ru (дата обращения 24.01.2021).
  2. Патент 2738605 С1 РФ. 5-Замещённые-6-гидрокси-2,3-дифенилпиримидин-4-(ЗН)-оны и способ их получения. ДА. Колесник, Е.В. Kyeaeea, T.Л. Семакова, О.Ю. Стрелова, И.П. Яковлев. 2020.
  3. GUSAR V. 2011.1: система моделирования острой токсичности [для моделирования]. А. Захаров, В. Поройков. Москва: 2011. (Электронная дистрибьюция).
  4. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с.
  5. STATISTICA 7.0: система статистического анализа [для статистического анализа]. «StatSoft» - Америка: 1984. (Электронная дистрибьюция).
  6. PASS Online. Way2Drug: [веб-ресурс]. Москва.ХЖЬ: www.way2drug.com/PASSOnline (дата обращения 24.01.2021).

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies